Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Eli Lilly & Co., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (loss) 2,189,700 (57,400) 1,763,200 1,344,900 1,937,700 1,451,700 952,500 1,902,900 1,726,100 1,110,100 1,390,200 1,355,300 2,116,800 1,208,400 1,412,000 1,456,500 1,495,700 1,253,900 1,327,200 4,241,600
Gain related to disposition of Elanco (3,680,500)
Gain on sale of antibiotic business in China (309,800)
Depreciation and amortization 387,700 411,000 366,300 362,300 375,000 362,900 348,900 435,700 445,700 382,300 369,300 350,300 367,500 358,400 324,400 273,600 340,700 288,000 247,400 356,500
Change in deferred income taxes (506,200) (844,300) (431,100) (559,400) 10,400 (1,070,600) (618,400) (506,600) (92,500) (296,000) (294,700) (119,100) (200,700) 159,700 (104,700) 11,200 85,800 (12,100) 61,100 (72,400)
Debt extinguishment loss 405,200
Stock-based compensation expense 120,200 215,600 161,500 131,200 92,900 85,100 92,100 101,000 75,300 90,100 91,900 85,500 87,800 71,700 76,800 71,800 81,600 75,500 79,500 75,800
Net investment (gains) losses (121,000) 64,500 65,800 14,200 (256,400) 130,800 119,500 426,100 93,100 247,000 (215,900) (302,200) (529,000) (144,500) (578,300) (186,700) (225,500) (50,100) (127,500)
Gains on sale of product rights (25,000) (1,853,900) (62,000) (94,500)
Acquired in-process research and development 622,600 2,975,100 97,100 105,000 168,900 19,000 80,000 153,000 376,600 174,000 25,000 299,300 366,300 241,800 52,300 77,700 25,000 136,900
Other changes in operating assets and liabilities, net of acquisitions and divestitures (3,172,200) 793,300 (840,200) 164,100 (836,000) 939,100 (72,100) (45,500) (474,500) (666,500) 221,200 (102,800) (515,200) 249,400 926,500 (1,408,100) 76,500 (247,300) (802,100) (714,300)
Other operating activities, net 192,300 485,600 (550,700) 168,300 149,200 361,300 (81,800) 32,600 6,700 185,100 188,500 131,100 121,700 (96,500) 196,900 111,800 418,700 124,500 240,900 (32,300)
Adjustments to reconcile net income (loss) to cash flows from operating activities (2,501,600) 2,246,900 (1,131,300) 385,700 (358,000) 733,100 (131,800) 596,300 430,400 521,200 385,300 342,100 (301,600) 598,200 1,083,400 (1,074,100) 468,000 256,200 (275,700) (3,930,300)
Net cash provided by operating activities (311,900) 2,189,500 631,900 1,730,600 1,579,700 2,184,800 820,700 2,499,200 2,156,500 1,631,300 1,775,500 1,697,400 1,815,200 1,806,600 2,495,400 382,400 1,963,700 1,510,100 1,051,500 311,300
Purchases of property and equipment (1,070,600) (970,300) (738,200) (668,500) (500,700) (617,200) (371,000) (365,400) (291,400) (336,800) (381,300) (300,300) (454,700) (393,100) (281,800) (258,300) (326,500) (263,400) (240,300) (203,700)
Proceeds from sales and maturities of short-term investments 37,000 45,600 48,100 61,500 38,300 25,500 30,900 26,700 800 25,300 17,300 4,000 10,900 7,600 74,400 36,800 20,300 26,900 53,500 35,900
Purchases of short-term investments (19,000) (19,400) (36,800) (23,000) (42,400) (32,100) (18,300) (14,600) (55,600) (1,300) (7,200) (19,400) (11,400) (8,600) (400) (33,700)
Proceeds from sales of and distributions from noncurrent investments 31,900 87,800 106,500 281,900 90,600 83,100 87,100 81,400 262,800 75,300 177,100 284,800 183,000 162,100 357,500 54,500 111,400 82,000 332,800 83,600
Purchases of noncurrent investments (256,000) (131,400) (197,400) (146,000) (126,100) (222,700) (134,700) (116,700) (219,800) (207,000) (211,600) (291,500) (135,000) (68,900) (71,800) (83,000) (50,800) (50,100) (86,000) (60,600)
Proceeds from sale of product rights 1,604,300 30,000 65,800
Cash paid for acquisitions, net of cash acquired (1,044,300) (327,200) (747,400) (849,300) (6,917,700)
Purchases of in-process research and development (580,500) (3,030,900) (98,100) (235,000) (54,900) (3,000) (80,000) (491,800) (102,800) (118,800) (150,000) (191,800) (364,800) (22,000) (241,400) (13,000) (77,700) (45,000) (196,900)
Cash distributed to Elanco upon disposition (374,000)
Cash received for sale of antibiotic business in China 354,800
Other investing activities, net (22,800) (666,200) 456,800 40,300 31,900 (222,800) 22,100 (133,400) 27,000 (53,200) 72,400 (21,900) 86,500 12,200 (47,300) 51,400 232,000 (141,500) 46,400 (385,600)
Net cash used for investing activities (2,924,300) (3,080,500) (459,100) (688,800) (860,500) (923,400) (463,900) (1,013,800) (379,000) (616,500) (483,300) (1,283,500) (674,100) (313,500) (210,400) (1,060,900) (41,400) (423,800) 61,000 (7,678,700)
Dividends paid (1,018,100) (1,016,200) (1,017,800) (1,017,200) (884,400) (882,200) (883,700) (885,500) (773,300) (770,400) (768,300) (774,800) (670,000) (671,600) (674,200) (671,300) (587,200) (587,400) (598,000) (637,200)
Net change in short-term borrowings 4,594,400 1,595,000 (1,498,000) (243,300) (375,900) 1,617,500 499,700 (2,500) (197,800) 200,000 (3,700) (579,900) (678,900) (1,984,100) 1,748,700 (63,500) (505,400) (286,100) 1,850,400
Proceeds from issuance of long-term debt 3,958,500 2,410,800 1,073,700 988,600 2,108,100 4,448,300
Repayments of long-term debt (849,900) (710,100) (100) (1,905,300) (200) (276,300) (2,266,100) (100) (200) (600,000)
Purchases of common stock (750,000) (1,500,000) (750,000) (500,000) (500,000) (300,000) (600,000) (3,500,000)
Other financing activities, net (31,600) (6,800) (15,600) (281,000) (13,700) (5,200) (7,600) (282,400) (600) (500) (14,900) (279,900) (41,400) (2,300) (3,500) (194,400) (4,900) (1,500) (193,700)
Net cash provided by (used for) financing activities 3,544,700 572,000 (1,033,400) 412,300 (1,141,400) (1,263,300) (123,700) (2,878,300) (1,526,500) (463,200) (1,083,200) (1,058,400) (1,291,500) (279,100) (1,673,200) 106,700 (1,113,600) (1,692,900) (885,800) 1,367,800
Effect of exchange rate changes on cash and cash equivalents 129,300 5,300 9,200 24,800 (128,200) (3,600) (69,400) 33,600 (220,700) 16,600 8,600 (10,200) 212,200 16,200 54,300 (66,700) (35,000) (119,800) 27,100 37,800
Net increase (decrease) in cash and cash equivalents 437,800 (313,700) (851,400) 1,478,900 (550,400) (5,500) 163,700 (1,359,300) 30,300 568,200 217,600 (654,700) 61,800 1,230,200 666,100 (638,500) 773,700 (726,400) 253,800 (5,961,800)

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Eli Lilly & Co. net cash provided by operating activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash used for investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Eli Lilly & Co. net cash used for investing activities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Net cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Eli Lilly & Co. net cash provided by (used for) financing activities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.